Most Recent
Bauer Consumer Media has won a five-year legal battle over Evergreen Television's Discover Downunder trade mark, with the Full Federal Court setting aside a prior IP Australia decision and deregistering the mark.
The sought-after commission at the centre of an unsuccessful common fund application in a class action over the use of toxic foam at a RAAF base near Katherine, NT has been revealed as 15% of any gross recovery in the case plus up to three and a half times the funder's costs.
A judge has tossed an application for a common fund order in a class action over the use of toxic foam on a RAAF base near Katherine, NT after a barrister for the lead applicants said the bid would be withdrawn if the judge appointed an independent "contradictor" to scrutinise the proposed funding structure.
Two generic pharmaceutical companies, Generic Partners and Apotex, have filed cross-claims alleging that Neurim Pharmaceuticals' patent for its insomnia drug Circadin is invalid and should be revoked.
A judge overseeing three toxic foam class actions against the Commonwealth of Australia has said he's not comfortable approving a common fund order which does not detail specific remuneration amounts for funder IMF Bentham.
Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.
ASIC is seeking approval from the High Court to appeal a judgment that let a former director of Gold Coast finance company MFS Group partially off the hook for $147.5 million in misappropriated funds, saying the High Court needs to clarify the scope of the word "officer" under the Corporations Act.
The applicants in a class action over exposure to allegedly toxic foam used on a government military base have struck back at the Commonwealth of Australia's argument that their claims were filed too late.
Three former executives of failed Gold Coast finance company MFS Group have lost their challenge to a ruling that they misappropriated $147.5 million in funds prior to the company's collapse.
Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.